FundedIQ
Health Care

Bioventus

Bioventus is a global leader of active orthopaedic healing, providing clinically proven and cost-effective therapies and diagnostics that help patients regain active lifestyles. Bioventus' products are known for their innovation, safety and effectiveness. The company is the recognized leader in bone stimulation devices and among the leading distributors of osteoarthritis joint fluid therapies. Key products include: - EXOGEN(r) Ultrasound Bone Healing System - SUPARTZ(r) Joint Fluid Therapy (US only) - DUROLANE(r) Hyaluronic Acid, Single Injection (Outside US only) Bioventus' adherence to high quality standards, commitment to evidence-based medicine and strong ethical behavior makes the company a trusted partner for thousands of physicians worldwide. Bioventus employs 500 people and generates about $240 million in yearly revenue. The company is headquartered in Durham, N.C. Prior to launch in 2012, Bioventus was operating as the Biologics Division of Smith & Nephew.

www.bioventus.com Durham, United States 1001-5000 employees
Total raised
$415M
Rounds
1
Latest
Post-IPO Debt
Apr 2022

Bioventus is a global leader of active orthopaedic healing, providing clinically proven and cost-effective therapies and diagnostics that help patients regain active lifestyles. Bioventus' products are known for their innovation, safety and effectiveness. The company is the recognized leader in bone stimulation devices and among the leading distributors of osteoarthritis joint fluid therapies. Key products include: - EXOGEN(r) Ultrasound Bone Healing System - SUPARTZ(r) Joint Fluid Therapy (US only) - DUROLANE(r) Hyaluronic Acid, Single Injection (Outside US only) Bioventus' adherence to high quality standards, commitment to evidence-based medicine and strong ethical behavior makes the company a trusted partner for thousands of physicians worldwide. Bioventus employs 500 people and generates about $240 million in yearly revenue. The company is headquartered in Durham, N.C. Prior to launch in 2012, Bioventus was operating as the Biologics Division of Smith & Nephew.

Bioventus has raised $415M across 1 round. Its most recent round was a Post-IPO Debt of $415M in Apr 2022. Full funding history, investors, and team are detailed below.

Funding history

1 round · 1 visible Unlock with plan

1 round on record.

Date
Round
Amount
Lead investor
Apr 26, 2022
Post-IPO Debt
$415M

Unlock the lead investor and full details for this round.

Unlock funding history →

People

Unlock with plan

Founders, executives, and decision-makers — sourced and refreshed weekly.

Name
Role
LinkedIn

See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.

Unlock people data →

Bioventus is featured in

Similar companies

Intellihealth

Intellihealth creates medical technology software that aids in diagnosing diseases associated with obesity. One of the company's primary offerings, Evolve, allows healthcare professionals to provide effective obesity treatment to patients, whether through telehealth or in-person consultations.

Venture - Series Unknown $5.2M
Ember Copilot

Ember Copilot is a Software Development firm offering a tool to reduces medical claim denials.

Seed $4.3M
Reimagine Care

Reimagine Care is a health care company that provides technology-enabled services to support community-based oncology care settings. It aims to make high-quality cancer care more affordable, accessible, and patient-centric. Reimagine Care partners with HC systems and independent physician oncology practices to support value-based oncology care delivery in the community. They do this by providing the people, processes, and a robust technology platform that enables the scalable and effective delivery of high-quality, patient-centric, lower-cost cancer care across multiple care sites, including the home. It was founded in 2020 and is based in Nashville, Tennessee.

Venture - Series Unknown $2.4M
QSimulate

QSimulate is currently hiring for various positions such as scientists, software engineers, project managers, and business development, as the team expands. Our office locations include Boston MA, Berkeley CA, and Ghent, Belgium. Remote options are also considered for technical roles. For further details, please contact us at info@qsimulate.com.

Seed
Function Health

100 Healthy Years • Your new routine of 120+ advanced lab tests explained by the world's top doctors

Series B $298M
Perelel

Perelel is a supplement manufacturer designed for various stages of a woman's reproductive life cycle.

Private Equity $27.0M
House Rx

House Rx is a health technology platform focused on improving affordability and patient access to specialty medications.

Series B $55.0M
DifferentKind

DifferentKind is a software solution designed for dental professionals to focus on patient needs, allowing them to enhance patient results and satisfaction. This ultimately leads to increased trust, loyalty, and revenue for dental practices. The software utilizes AI technology for clinical consultations and executive decision-making.

Seed $300k
NextSense

NextSense opens mind wellbeing with genuine information experiences and useful, logical insight for everyday living. It plans to catalyze cerebrum wellbeing in science and culture. The organization was established in 2020 and is settled in Mountain View, California.

Series A $16.3M
MR3Health

MR3Health is a unique new organization that brings an inventive mix of administration and demonstrated innovation to patients and guarantors to save lives impacted by diabetic neuropathy and lower the expenses of medical services. MR3Health is extraordinarily situated for progress with various assets obscure to most new businesses. These incorporate existing licenses, a FDA cleared clinical gadget upheld by clinical preliminaries, and a supervisory crew with an abundance of business, assembling, and clinical experience. It was sent off in 2015 and is settled in San Antonio, Texas.

Venture - Series Unknown $690k
MiSalud

MiSalud offers a unique combination of personalized preventative wellness services, along with traditional healthcare via Spanish speaking physicians.

Venture - Series Unknown
Synchron

Synchron is a leading implantable brain computer interface company. The stentrode is the first commercial implantable brain computer interface to receive an FDA IDE for in human clinical trials.

Series D $200M
Free · Every Monday

Know which startups just got funded. Every week.

Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.

Free. Sent every Monday. Unsubscribe anytime.